Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients
Table 1
Summary of the CD8 T cell responses to the Sp17 peptides by DLBCL patients.
Patients
Diagnosis
HLA status
Pattern of Sp17 staining
-IFN response to peptides per 50,000 cells
Sp17(1)
Sp17(2)
Sp17(3)
No peptide
HIV-1
PHA
Significant response
1
DLBCL(dn)
Cytoplasm and <10% nuclei
2
DLBCL(dn)
Scattered nuclei
5
DLBCL(dn)
—
7
DLBCL(dn)
<10% nuclei
8
DLBCL(dn)
ND
9
DLBCL(dn)
—
12
DLBCL(dn)
Weak cytoplasm and < 5% nuclei
14
DLBCL(dn)
ND
18
DLBCL(dn)
Weak cytoplasm and <5% nuclei
19
DLBCL(t)
<10% nuclei
21
DLBCL(dn)
Cytoplasm + scattered < 5% nuclei
22
DLBCL(t)
ND
37
DLBCL(dn)
<5% nuclei
39
T cell rich
—
No significant response
3
DLBCL(dn)
0201+
—
4
DLBCL(dn)
0201+
—
6
DLBCL(dn)
0201+
—
10
DLBCL(dn)
0101+
ND
11
DLBCL(dn)
0201+
ND
13
DLBCL(dn)
0201+
—
15
DLBCL(dn)
0101+
ND
16
DLBCL(dn)
0201+
—
17
DLBCL(dn)
0201+
ND
20
DLBCL(dn)
0101+
Cytoplasm + scattered < 5% nuclei
38
DLBCL(dn)
0201+
ND
40
DLBCL(dn)
0201-negative, 0101-negative
ND
41
DLBCL(dn)
0201-negative, 0101-negative
—
42
DLBCL(dn)
0201-negative, 0101-negative
ND
43
DLBCL(dn)
0201-negative, 0101-negative
—
>500
48
DLBCL(dn)
0201-negative, 0101-negative
—
49
DLBCL(dn)
0201-negative, 0101-negative
ND
Healthy donors
1
0201+
ND
2
0201+
ND
3
0201+
ND
4
0301+
ND
DLBCL(dn): de novo diffuse large B cell lymphoma; DLBCL(t): diffuse large B cell lymphoma transformed; TCR: T cell rich B cell lymphoma. The results +/− are from triplicate ELISPOT cultures. The SD was calculated using standard techniques. Significant -IFN responses are highlighted in bold. ND, not determined.
